4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Show more...
CEO
Dr. Jason Loveridge B.Sc., B.Sc, Ph.D., FRSM
Karyawan
33
Negara
DE
ISIN
DE000A3E5C40
WKN
000A3E5C4
Pencatatan
0 Comments
Bagikan pendapatmu
FAQ
Berapa harga saham 4 SC hari ini?▼
Harga saat ini dari VSC.XETRA adalah €2.98 EUR — naik sebesar +0% dalam 24 jam terakhir. Pantau kinerja harga saham 4 SC lebih dekat di grafik.
Apa simbol saham 4 SC?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham 4 SC diperdagangkan dengan simbol VSC.XETRA.
Berapa jumlah karyawan 4 SC?▼
Per April 08, 2026, perusahaan memiliki 33 karyawan.